Merck KGaA’s Rare Tumor Strategy Takes Shape With $3.9B SpringWorks Acquisition

Merck KGaA is building up its portfolio and pipeline with a $3.9 billion deal to acquire SpringWorks Therapeutics, a company with two FDA-approved rare tumor drugs, both of which offer ...